Renal Cell Carcinoma: Update Bulletin #3 [March 2018]
This edition presents key opinion leader (KOL) views on recent developments in the renal cell carcinoma (RCC) market. Topics covered include; the success of Roche’s Phase III IMmotion151 trial of atezolizumab (Tecentriq) in combination with Avastin (bevacizumab) in meeting its co-primary endpoint of investigator-assessed progression-free survival (PFS); AVEO Oncology and EUSA Pharma presenting positive preliminary findings from the Phase II portion of the TiNivo study of Fotivda (tivozanib) in combination with Opdivo (nivolumab; BMS) for the treatment of metastatic RCC; and, in light of recent FDA Breakthrough Therapy Designations, the potential for avelumab (Bavencio; Merck Group/Pfizer) in combination with Inlyta (axitinib; Pfizer), and pembrolizumab (Keytruda; Merck & Co.) in combination with Lenvima (lenvatinib; Eisai), to be successful first-line therapies for advanced or metastatic RCC.
Business Questions:
Business Questions:
- How do KOLs view the data released from Roche’s Phase III IMmotion151 trial of atezolizumab in combination with Avastin?
- How is the safety and tolerability of atezolizumab combinaed with Avastin viewed as a treatment for RCC?
- While the IMmotion151 trial was successful in meeting its primary co-endpoint of investigator-assessed PFS, it fell short of meeting its secondary outcome measure of centrally assessed PFS?
- How do KOLs interpret this apparent discrepancy in the data?
- How are the positive preliminary findings from the Phase II portion of the TiNivo study of Fotivda in combination with Opdivo viewed?
- Amidst the plethora of combinations set to emerge in the first-line setting, how do KOLs rate the chances of Fotivda/Opdivo competing?
- How is the tolerability profile of Fotivda/Opdivo viewed by KOLs?
- What are the prospects for success for TKI/IO combinations in the first-line treatment of advanced/metastatic RCC?
- Avelumab/Inlyta and Keytruda/Lenvima combination regimens have recently been granted Breakthrough Therapy Designation by the FDA. How do the KOLs view these as potential first-line combination treatments for advanced/metastatic RCC?
